Locally advanced head and neck squamous cell carcinoma (LA-HNSCC) research hub

A phase II trial evaluating treatment intensification with Ezabenlimab in patients with PD-L1–expressing, locally advanced head and neck squamous cell carcinoma (LA-HNSCC) with minimal residual disease (MRD) as detected by circulating tumor DNA (ctDNA) after curative-intent chemoradiation

This study is looking at a new treatment called Ezabenlimab for a type of head and neck cancer. It focuses on patients who have small traces of cancer left after their first treatment, to see if adding Ezabenlimab can prevent the cancer from coming back.